We continue to receive GranuFlo lawsuit inquiries from individuals who allegedly suffered serious heart side effects following treatment with these products. It’s not at all surprising that cases are multiplying at such a rapid rate.
New York, New York (PRWEB) June 14, 2013
GranuFlo lawsuit claims filed in the wake of last year’s recall for GranuFlo and NaturaLyte dialysis drugs continue to mount in the federal multidistrict litigation now underway in U.S. District Court, District of Massachusetts. According to an MDL Statistics Report issued on May 14th by the U.S. Judicial Panel on Multidistrict Litigation (JPML), at least 161 GranuFlo recall claims have been filed in the federal litigation since it was established in March. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“GranuFlo and NaturaLyte were widely used by dialysis clinics throughout the country before they were recalled. We continue to receive GranuFlo lawsuit inquiries from individuals who allegedly suffered serious heart side effects following treatment with these products. It’s not at all surprising that cases are multiplying at such a rapid rate,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the GranuFlo recall.
GranuFlo and NaturaLyte are manufactured by Fresenius Medical Care, which according to the New York Times, treats more than a third of the estimated 400,000 Americans receiving dialysis and is the leading supplier of dialysis machines and disposable products. GranuFlo and NaturaLyte were widely used at Fresenius’s own dialysis clinics, and were also used to treat an estimated 125,000 patients at clinics outside of the Fresenius network.*
Both GranuFlo and Naturalyte were the subject of an “Urgent Product Notification” Fresenius issued to its customer clinics in March of 2012 that warned of possible heart risks associated with the products. Several months later, the U.S. Food & Drug Administration (FDA) deemed the notification a Class I GranuFlo recall, a designation that is only granted when a medical product poses a significant risk of serious injury or death.** According to The New York Times, the FDA launched an investigation into the timing of the GranuFlo recall, after learning that Fresenius had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte, and advised doctors to adjust their dosage to avoid these dangers.*
According to court documents, the GranuFlo recall litigation was established by an order of the JPML on March 29th in anticipation of a large number of claims. At the time, 11 GranuFlo lawsuits were transferred to the proceeding. Plaintiffs in these lawsuits allege Fresenius Medical Care was aware of the heart risks associated with GranuFlo and NaturaLyte, but failed to provide adequate warnings regarding those risks.
Dialysis patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo and NaturaLyte may be entitled to file a Granuflo lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
*http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm; FDA, March 29, 2013
**nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP